Source:http://linkedlifedata.com/resource/pubmed/id/21613256
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2011-7-15
|
pubmed:abstractText |
We evaluated 190 children with very high-risk leukemia, who underwent allogeneic hematopoietic cell transplantation in 2 sequential treatment eras, to determine whether those treated with contemporary protocols had a high risk of relapse or toxic death, and whether non-HLA-identical transplantations yielded poor outcomes. For the recent cohorts, the 5-year overall survival rates were 65% for the 37 patients with acute lymphoblastic leukemia and 74% for the 46 with acute myeloid leukemia; these rates compared favorably with those of earlier cohorts (28%, n = 57; and 34%, n = 50, respectively). Improvement in the recent cohorts was observed regardless of donor type (sibling, 70% vs 24%; unrelated, 61% vs 37%; and haploidentical, 88% vs 19%), attributable to less infection (hazard ratio [HR] = 0.12; P = .005), regimen-related toxicity (HR = 0.25; P = .002), and leukemia-related death (HR = 0.40; P = .01). Survival probability was dependent on leukemia status (first remission vs more advanced disease; HR = 0.63; P = .03) or minimal residual disease (positive vs negative; HR = 2.10; P = .01) at the time of transplantation. We concluded that transplantation has improved over time and should be considered for all children with very high-risk leukemia, regardless of matched donor availability.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1528-0020
|
pubmed:author |
pubmed-author:CampanaDarioD,
pubmed-author:Coustan-SmithElaineE,
pubmed-author:DallasMariM,
pubmed-author:GanKwanK,
pubmed-author:HandgretingerRupertR,
pubmed-author:HartfordChristineC,
pubmed-author:LaverJoseph HJH,
pubmed-author:LeungWingW,
pubmed-author:PeiDeqingD,
pubmed-author:PillaiAshaA,
pubmed-author:PuiChing-HonCH,
pubmed-author:RibeiroRaul CRC,
pubmed-author:RubnitzJeffrey EJE,
pubmed-author:SandlundJohn TJT,
pubmed-author:SrinivasanAshokA,
pubmed-author:TriplettBrandon MBM,
pubmed-author:YangJieJ
|
pubmed:issnType |
Electronic
|
pubmed:day |
14
|
pubmed:volume |
118
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
223-30
|
pubmed:meshHeading |
pubmed-meshheading:21613256-Child,
pubmed-meshheading:21613256-Cohort Studies,
pubmed-meshheading:21613256-Female,
pubmed-meshheading:21613256-Follow-Up Studies,
pubmed-meshheading:21613256-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:21613256-Humans,
pubmed-meshheading:21613256-Leukemia,
pubmed-meshheading:21613256-Male,
pubmed-meshheading:21613256-Neoplasm, Residual,
pubmed-meshheading:21613256-Neoplasm Staging,
pubmed-meshheading:21613256-Retrospective Studies,
pubmed-meshheading:21613256-Risk Factors,
pubmed-meshheading:21613256-Survival Analysis,
pubmed-meshheading:21613256-Tissue Donors,
pubmed-meshheading:21613256-Treatment Outcome
|
pubmed:year |
2011
|
pubmed:articleTitle |
High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.
|
pubmed:affiliation |
Department of Oncology, St Jude Children's Research Hospital, Memphis, TN 38105-2794, USA. wing.leung@stjude.org
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Evaluation Studies,
Research Support, N.I.H., Extramural
|